Comparative Liquid Biopsy Testing for KRAS Mutations From Plasma Cell‐Free DNA ( cfDNA ) and Extracellular Vesicles in Lung Adenocarcinoma
Cancer Reports · 2026
DOI: 10.1002/cnr2.70517 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Reports, 2026. Verfasst von Caeli J Zahra und 9 weiteren Autor:innen. Beteiligte Einrichtung: UQ Thoracic Research Centre, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Australia. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Extracellular Vesicles, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Background
Liquid biopsy has emerged as a promising, minimally invasive tool to detect cancer biomarkers. Extracellular vesicles (EVs) are secreted into biofluids to transport cargo such as DNA and are a potential biosource for liquid biopsy biomarkers. To determine the optimal use of liquid biopsy for diagnosing mutations in lung adenocarcinoma (LUAD), we compared the KRAS mutation status in DNA isolated from four different plasma fractions, including EVs.
Methods
Plasma was collected from 58 participants diagnosed with LUAD (early‐stage (I, II), n = 30; late‐stage (IIIB, IV), n = 28) with known KRAS mutation ( KRAS mt ) or wild‐type KRAS ( KRAS wt). Three distinct plasma‐derived fractions were prepared by sequential differential ultracentrifugation aiming to isolate EVs (pellets 1, 2, 3 (P1–P3)). These were tested together with the corresponding plasma supernatant (SUP) for the presence of KRAS G12/G13 mutations by droplet digital PCR (ddPCR).
Results
In early‐stage KRAS mt LUAD, mutations were detected by ddPCR in only 1 of 15 processed plasma supernatant samples and 1 of 15 P3 samples, but not in any P1 or P2 pellets. In late‐stage KRAS mt LUAD, mutations were detected in 13/14 of SUP samples, but only in a small fraction of the pellet preparations: P1 (0/14), P2 (2/14) and P3 (2/13) samples.
Conclusion
We conclude that ddPCR testing of plasma supernatant achieved high overall agreement with tumour KRAS mt status. There was varying abundance of KRAS detected in the plasma fractions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UQ Thoracic Research Centre, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Australia.
- Thoracic Medicine, The Prince Charles Hospital, Metro North Hospital and Health Service, Brisbane, Australia.
ORCID-Profile: Caeli J Zahra, Tian Mun Chee, Edward K H Stephens, Brielle A Parris, Hannah E O'Farrell, Anita F Goldsworthy, Ian A Yang, Kwun M Fong
Förderung
- National Health and Medical Research Council
Zitieren
APA
Zahra, C. J., Chee, T. M., Stephens, E. K. H., Keir, E. J., Parris, B. A., O'Farrell, H. E., Goldsworthy, A. F., Bowman, R. V., Yang, I. A., & Fong, K. M. (2026). Comparative Liquid Biopsy Testing for KRAS Mutations From Plasma Cell‐Free DNA ( cfDNA ) and Extracellular Vesicles in Lung Adenocarcinoma. Cancer Reports. https://doi.org/10.1002/cnr2.70517
Vancouver
Zahra CJ, Chee TM, Stephens EKH, Keir EJ, Parris BA, O'Farrell HE, et al. Comparative Liquid Biopsy Testing for KRAS Mutations From Plasma Cell‐Free DNA ( cfDNA ) and Extracellular Vesicles in Lung Adenocarcinoma. Cancer Reports. 2026. doi:10.1002/cnr2.70517
BibTeX
@article{Zahra2026,
author = {Zahra, Caeli J and Chee, Tian Mun and Stephens, Edward K H and Keir, Elizabeth J and Parris, Brielle A and O'Farrell, Hannah E and Goldsworthy, Anita F and Bowman, Rayleen V and Yang, Ian A and Fong, Kwun M},
title = {Comparative Liquid Biopsy Testing for KRAS Mutations From Plasma Cell‐Free DNA ( cfDNA ) and Extracellular Vesicles in Lung Adenocarcinoma},
journal = {Cancer Reports},
year = {2026},
doi = {10.1002/cnr2.70517}
}
EUVIMED